Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients

BACKGROUND: It is still unclear whether patients with advanced non‐small cell lung cancer (NSCLC), with disease progression after initial immune checkpoint inhibitor (ICI) therapy, would benefit from ICIs readministration. PATIENTS AND METHODS: We retrospectively collected data from patients with ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Torasawa, Masahiro, Yoshida, Tatsuya, Takeyasu, Yuki, Shimoda, Yukiko, Tateishi, Akiko, Matsumoto, Yuji, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Takahashi, Kazuhisa, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278515/
https://www.ncbi.nlm.nih.gov/pubmed/37062059
http://dx.doi.org/10.1002/cam4.5939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278515/
https://www.ncbi.nlm.nih.gov/pubmed/37062059
http://dx.doi.org/10.1002/cam4.5939

Ejemplares similares